Corrado Advisors’s Cyclerion Therapeutics CYCN Stock Holding History

Corrado Advisors’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1	Closed	-$13	–	177
2022 Q4	$13	Buy	+1	New	+$12	﹤0.01%	414

Other funds holding CYCN

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Corrado Advisors's CYCN Position: Q1 2023 in Review

Corrado Advisors sold out of Cyclerion Therapeutics (CYCN) in Q1 2023, closing a stake of 1 share — an estimated $13 sold.

Corrado Advisors first reported a position in CYCN in Q4 2022 and held it in 1 quarter. The position peaked at $13 in Q4 2022. 34 funds tracked by Wall St. Rank hold CYCN as of Q1 2023.

Corrado Advisors reported no remaining Cyclerion Therapeutics position as of Q1 2023 after selling out during the quarter.
Corrado Advisors sold 1 Cyclerion Therapeutics share in Q1 2023, an estimated $13.
Corrado Advisors first reported a position in Cyclerion Therapeutics in Q4 2022 and held it in 1 quarter.
Corrado Advisors's Cyclerion Therapeutics position peaked at $13 in Q4 2022.
34 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2023.

Based on Corrado Advisors's 13F filing for Q1 2023, filed 3 May 2023.